* André, T. et al. (2026). Clinical utility of the Idylla CDx MSI test in identifying MSI-H mCRC patients eligible for nivolumab monotherapy or in combination with ipilimumab therapy (CheckMate 8HW phase III trial). J Clin Oncol 44(2). https://doi.org/10.1200/JCO.2026.44.2_suppl.28
Idylla™ CDx MSI Test (A0220/6) is approved in the US under P250005 and is CE-marked in Europe in compliance with the EU IVD Regulation 2017/746 (IVDR). Launch in Europe is planned EO March 2026.